证券代码：600226 证券简称：瀚叶股份 公告编号：2023-054 浙江瀚叶股份有限公司 第九届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江瀚叶股份有限公司（以下简称"公司"）第九届董事会第三次会议通知于 2023 年 7 月 28 日以电子邮件和书面方式发出。会议于 2023 年 8 月 9 日以现场结合通讯方 式召开，本次会议由董事长崔巍先生主持，会议应出席董事 9 人，实际出席董事 9 人。 会议的召开符合《中华人民共和国公司法》和《浙江瀚叶股份有限公司章程》及有关 法律、法规的要求。会议审议并以书面表决方式通过了如下议案： 一、2023 年半年度报告及摘要； 二、2023 年上半年度亨通财务有限公司的风险持续评估报告。 表决结果：同意 5 票，反对 0 票，弃权 0 票。董事崔巍、张荆京、沈新华、吴燕 回避表决。 内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《2023年上 半年度亨通财务有限公司的风险持续评估报告》。 特此公告。 浙江瀚叶股份有限公司董 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥129,246,950.88, a decrease of 18.48% compared to ¥158,545,781.18 in the same period last year[6]. - The net profit attributable to shareholders for Q1 2023 was ¥42,993,520.28, representing a significant decline of 87.11% from ¥333,681,327.24 in the previous year[6]. - The basic and diluted earnings per share for Q1 2023 were both ¥0.01, down 90.91% from ¥0.11 in the previous year[7]. - Total operating revenue for Q1 2023 was CNY 129,246,950.88, a decrease of 18.43% compared to CNY 158,545,781.18 in Q1 2022[24]. - Net profit for Q1 2023 was CNY 42,065,651.00, a significant decline from CNY 333,617,734.31 in Q1 2022[25]. - Earnings per share for Q1 2023 were CNY 0.01, compared to CNY 0.11 in Q1 2022[26]. - Research and development expenses for Q1 2023 were CNY 1,730,509.09, a decrease of 58.65% from CNY 4,178,493.77 in Q1 2022[25]. - The company reported investment income of CNY 53,805,335.60 in Q1 2023, down from CNY 382,723,350.44 in Q1 2022[25]. - Other comprehensive income for Q1 2023 was CNY -278,592.39, compared to CNY 1,027,556.22 in Q1 2022[26]. Cash Flow - The company reported a net cash flow from operating activities of -¥24,167,141.55, primarily due to tax payments for the previous year[7]. - In Q1 2023, cash inflow from operating activities totaled ¥157,300,641.46, a significant increase from ¥99,547,233.92 in Q1 2022, representing a growth of approximately 58%[29]. - Cash outflow from operating activities in Q1 2023 was ¥181,467,783.01, compared to ¥102,160,782.20 in Q1 2022, resulting in a net cash flow from operating activities of -¥24,167,141.55, worsening from -¥2,613,548.28 in the previous year[30]. - Cash inflow from investment activities was ¥103,039,581.61 in Q1 2023, down from ¥454,260,536.23 in Q1 2022, indicating a decline of approximately 77%[30]. - Cash outflow from investment activities surged to ¥278,438,275.53 in Q1 2023, compared to ¥105,493,761.44 in Q1 2022, leading to a net cash flow from investment activities of -¥175,398,693.92, a significant drop from ¥348,766,774.79 in the previous year[30]. - Cash inflow from financing activities reached ¥163,887,500.00 in Q1 2023, up from ¥80,892,270.00 in Q1 2022, marking an increase of approximately 102%[30]. - Net cash flow from financing activities improved to ¥142,268,765.58 in Q1 2023, compared to ¥12,226,855.57 in Q1 2022, reflecting a substantial increase[30]. - The ending balance of cash and cash equivalents as of Q1 2023 was ¥819,171,042.15, compared to ¥709,677,184.19 at the end of Q1 2022, showing an increase of approximately 15%[30]. - The company received tax refunds amounting to ¥645,120.09 in Q1 2023, an increase from ¥484,847.66 in Q1 2022, representing a growth of about 33%[29]. - The company reported a significant increase in cash received from other operating activities, totaling ¥35,891,076.35 in Q1 2023, compared to ¥4,835,270.14 in Q1 2022, indicating a growth of over 640%[29]. - The company’s cash outflow for employee compensation was ¥26,536,536.28 in Q1 2023, up from ¥23,392,528.57 in Q1 2022, reflecting an increase of approximately 9%[29]. Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,647,838,905.91, an increase of 1.14% from ¥3,318,711,397.55 at the end of the previous year[7]. - The equity attributable to shareholders at the end of Q1 2023 was ¥3,136,266,199.42, a decrease of 1.22% from ¥3,088,326,777.97 at the end of the previous year[7]. - Total assets as of Q1 2023 amounted to CNY 3,647,838,905.91, slightly up from CNY 3,606,859,389.37 in the previous year[21]. - Total liabilities for Q1 2023 were CNY 270,609,949.05, down from CNY 338,878,271.15 in Q1 2022[21]. - Shareholders' equity increased to CNY 3,377,228,956.86 in Q1 2023 from CNY 3,267,981,118.22 in Q1 2022[21]. - Accounts receivable increased to ¥58,225,614.70 from ¥47,479,862.03 year-over-year[19]. - The total current assets decreased to ¥1,136,184,215.94 from ¥1,208,773,229.51 as of December 31, 2022[19]. - Long-term equity investments rose to ¥1,551,164,309.89 from ¥1,499,365,783.91 year-over-year[19]. - Other non-current financial assets increased to ¥185,706,582.89 from ¥86,716,968.77 as of December 31, 2022[19]. - The company's fixed assets decreased to ¥327,785,236.02 from ¥337,571,762.22 year-over-year[19]. - The company reported a significant increase in prepayments to ¥5,060,066.82 from ¥2,982,778.94 year-over-year[19]. Corporate Actions - The company completed the acquisition of 51% equity in Hengtong Precision Copper Foil Technology (Deyang) Co., Ltd. for ¥81.6 million, which was finalized on February 10, 2023[7]. - The company has ongoing litigation regarding accounts receivable and restructuring transaction intention funds, with favorable court rulings[15][16]. - The company is actively monitoring the operational status of its subsidiaries and their financial obligations[15].

Financial Performance - The company's operating revenue for 2022 was ¥602,084,675.08, a decrease of 11.62% compared to ¥681,244,921.86 in 2021[26] - The net profit attributable to shareholders for 2022 was ¥486,018,953.67, representing a 29.59% increase from ¥375,030,039.69 in 2021[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥101,601,176.08, down 24.10% from ¥133,863,416.13 in the previous year[26] - The net cash flow from operating activities was ¥25,217,062.81, a significant decrease of 76.05% compared to ¥105,272,394.01 in 2021[26] - As of the end of 2022, the net assets attributable to shareholders were ¥3,088,326,777.97, an increase of 16.12% from ¥2,659,499,359.78 at the end of 2021[26] - Total assets at the end of 2022 amounted to ¥3,318,711,397.55, reflecting a 12.70% increase from ¥2,944,798,906.16 in 2021[26] - Basic earnings per share increased by 33.33% to CNY 0.16 in 2022 compared to CNY 0.12 in 2021[27] - The net profit attributable to shareholders decreased significantly in Q4 2022 to -CNY 60,601,626.77, primarily due to large credit impairment losses and asset impairment losses[32] - The operating revenue for Q4 2022 was CNY 172,307,979.46, showing stability in revenue generation across the quarters[34] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 22,259,241.28 in Q1 2022, but dropped to -CNY 23,546,465.04 in Q4 2022[31] Cash Flow and Investments - The company plans to not distribute cash dividends for the year 2022, with a proposed cash repurchase amount of ¥50,038,162.65, equivalent to a dividend payout ratio of 10.30%[6] - The company reported a net cash flow from operating activities of CNY 59,433,494.12 in Q4 2022, indicating a positive cash flow situation[31] - The company completed the transfer of several subsidiaries, generating a total investment income of CNY 66,340,000.00 in 2022[32] - The company plans to invest approximately 5 billion yuan in a 50,000 tons/year electrolytic copper foil project, which is currently progressing steadily[43] - The company made a significant equity investment of CNY 101,346,000.00 for a 0.70% stake in Urumqi Bank[123] - The acquisition of 51% stake in Hengtong Precision Copper Foil was completed for CNY 81,600,000.00, with an additional capital contribution of CNY 165,112,500.00 planned[125] Risk Management - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8] - There are no violations of decision-making procedures regarding external guarantees[9] - The company has detailed potential risks in the management discussion and analysis section of the report[11] - The company is actively managing risks related to accounts receivable and has initiated legal proceedings to recover overdue amounts totaling 229.30 million yuan[45] - The company faces risks in its strategic transformation and pesticide business due to increased competition and stringent environmental regulations[148] - The company is closely monitoring raw material price trends to minimize the impact of price fluctuations on operating performance, implementing inventory management and production process optimization[150] Research and Development - The company's R&D expenses decreased by 32.73% to CNY 13.16 million, primarily due to changes in product revenue structure[62] - The company has established multiple laboratories equipped with advanced experimental equipment to support R&D efforts[59] - The company is collaborating with research institutions to drive product innovation and improve production efficiency in its biotechnology sector[43] - The company aims to enhance its core competitiveness by investing in energy business areas while reducing loss-making operations[58] - The company plans to enhance its R&D system, strengthen partnerships with research institutions, and attract high-end talent[146] Market Trends and Challenges - The feed additive industry faced significant challenges in 2022, with soybean meal prices reaching a historical high of 5,702 yuan/ton on November 20, 2022[49] - The overall market for L-Tryptophan remained under pressure due to weak downstream demand, leading to prolonged low pricing before the fourth quarter[80] - The company faces competitive disadvantages in the supply chain compared to leading firms that have better control over raw material costs and production efficiencies[79] - The pesticide industry is projected to see a revenue increase of 10% in production value within industrial parks by 2025[53] - The market for veterinary drugs is shifting towards products that are efficient, safe, and have low residues, indicating a change in consumer preferences[140] Corporate Governance - The company has implemented a strict internal control system in accordance with regulations, enhancing management and risk prevention capabilities[198] - The internal control audit report issued by Tianjian Accounting Firm confirmed the effectiveness of the internal control system with a standard unqualified opinion[199] - The company maintains independence from its controlling shareholders in assets, personnel, finance, and operations, adhering to the principle of five separations and five independences[158] - The company has conducted five shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[156] - The company’s independent directors are involved in the profit distribution decision-making process, ensuring transparency and accountability[192] Strategic Initiatives - The company plans to focus on product transformation, scale expansion, and sales channel development in its pesticide business to mitigate future risks[70] - The company aims to transition its pesticide products from raw materials to formulated products, with several pesticide formulations already registered and approved[144] - The company plans to continue expanding its market presence and exploring new investment opportunities in the upcoming fiscal year[123] - The company is focusing on expanding its market presence through strategic leadership appointments and partnerships in the technology sector[165] - The company plans to invest 100 million RMB in digital marketing to boost brand awareness and user engagement in the upcoming year[170]

Financial Performance - The company's operating revenue for 2022 was ¥602,084,675.08, a decrease of 11.62% compared to ¥681,244,921.86 in 2021[26] - The net profit attributable to shareholders for 2022 was ¥486,018,953.67, representing a 29.59% increase from ¥375,030,039.69 in 2021[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥101,601,176.08, down 24.10% from ¥133,863,416.13 in the previous year[26] - The net cash flow from operating activities decreased by 76.05% to ¥25,217,062.81 from ¥105,272,394.01 in 2021[26] - As of the end of 2022, the net assets attributable to shareholders were ¥3,088,326,777.97, an increase of 16.12% from ¥2,659,499,359.78 at the end of 2021[26] - Total assets at the end of 2022 were ¥3,318,711,397.55, reflecting a 12.70% increase from ¥2,944,798,906.16 in 2021[26] - Basic and diluted earnings per share were both 0.16 yuan, representing a 33.33% increase compared to 0.12 yuan in 2021[27] - The weighted average return on equity increased to 17.00%, up by 2.72 percentage points from 14.28% in 2021[27] - The company reported a significant increase in investment income, rising by 38.97% to CNY 669.91 million[54] - The company's operating costs decreased by 7.35% to CNY 521.57 million compared to the previous year[53] Strategic Development - The company is focusing on expanding its energy sector, particularly in copper and aluminum foil materials, as part of its strategic development[36] - The company aims to enhance its profitability and risk resistance by investing in high-tech and high-potential strategic emerging industries[36] - The company is committed to the "self-controllable" national strategy, aligning with the country's carbon peak and carbon neutrality goals[36] - The company plans to invest approximately RMB 5 billion to construct a 50,000 tons/year electrolytic copper foil project, which is currently progressing steadily[37] - The company is focusing on the energy sector as a strategic priority for future development, optimizing its industrial structure[37] Market and Industry Trends - The global pig output reached 69.995 million heads in 2022, an increase of 4.3% year-on-year, indicating recovery in the pig farming industry[43] - The veterinary drug and feed additive market in China is expected to see accelerated integration, with a focus on production quality standards and compliance with new GMP requirements by June 1, 2022[44] - The pesticide industry is projected to reduce the number of production enterprises from 1,705 in 2020 to below 1,600 by 2025, with a target of cultivating 10 enterprises with a revenue exceeding 5 billion yuan[45] - By 2025, the revenue from large-scale pesticide enterprises is expected to exceed 250 billion yuan, reflecting a significant consolidation in the industry[46] - The company is adapting to stricter environmental regulations, which are expected to accelerate the elimination of outdated production capacities in the pesticide sector[46] Research and Development - The company has established partnerships with domestic universities and research institutions to enhance product development and technological upgrades in its chemical business[49] - The company aims to focus on producing environmentally friendly and eco-friendly pesticide formulations, with over 40 registered products covering various types of pesticides[48] - The company is committed to achieving a green and low-carbon development model in the pesticide industry, promoting technological innovation and process upgrades[46] - The company has optimized production processes for Monensin and L-Tryptophan, enhancing market competitiveness[94] Governance and Compliance - The company has established a governance structure that ensures equal rights for all shareholders and maintains good communication channels[133] - The company emphasizes investor relations and has engaged with stakeholders through various communication channels to protect their interests[134] - The company has not reported any significant changes in competition or business overlap with its controlling shareholders[136] - The company has established measures to ensure the independence of its operations from its controlling shareholders[136] - The company has committed to maintaining independence in assets, personnel, finance, organization, and business operations[136] Environmental Management - The company has implemented a comprehensive environmental management system, including risk identification and emergency response training for employees[194] - The company strictly adheres to national environmental laws and regulations, ensuring that major pollutants are consistently within the emission limits set by government authorities[195] - Baike Bio's wastewater treatment center has a capacity of 8000T/D, with supporting facilities for anaerobic pretreatment (2400T/D) and high-concentration pretreatment (4000T/D)[187] - The company achieved compliance with wastewater discharge standards, with COD at 33.21t/a, ammonia nitrogen at 3.32t/a, sulfur dioxide at 67.2t/a, nitrogen oxides at 96t/a, and particulate matter at 9.6t/a, all below the permitted limits[185] Shareholder and Board Activities - The company held five shareholder meetings during the reporting period, ensuring compliance with relevant regulations and protecting shareholder rights[134] - The company has seen no changes in shareholding for several key executives, indicating stability in management[141] - The company held a total of 18 board meetings in 2022, with 9 meetings attended in person and 0 absences[158] - The company approved the transfer of 100% equity of subsidiaries and the cancellation of repurchased shares during the eighth board meeting[155] Future Outlook - The company plans to reduce the production of antibiotic veterinary drugs and shift towards amino acid feed additives, enhancing product technology content and added value[117] - The company plans to increase its workforce by 15% to support growth initiatives and enhance operational capabilities[149] - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[149] - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative biotechnology solutions[147]

证券代码：600226 证券简称：ST 瀚叶 公告编号：2023-024 浙江瀚叶股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 4 日(星期二)至 4 月 11 日(星期二)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （600226@hugeleafgroup.com）进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 浙江瀚叶股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、 财务状况，公司计划于 2023 年 4 月 12 日下午 15:00-16:00 举行 2022 年度业绩说 明会，就投资者关心的问题进行交流。 （二）会议召开地点：上证路演中心 （三）会议召开方式： ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥117,485,868.72, a decrease of 26.96% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥149,010,880.35, down 44.59% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,224,953.11, a decrease of 18.15% compared to the same period last year[6]. - The basic earnings per share for Q3 2022 was ¥0.05, a decline of 44.44% year-on-year[8]. - The diluted earnings per share for Q3 2022 was also ¥0.05, reflecting a 44.44% decrease compared to the previous year[8]. - The weighted average return on equity was 4.82%, a decrease of 3.70 percentage points from the previous year[8]. - Total operating revenue for the first three quarters of 2022 was RMB 429,776,695.62, a decrease of 12% compared to RMB 488,512,672.79 in the same period of 2021[31]. - The total profit for the current period is CNY 586,100,004.65, compared to CNY 453,270,916.85 in the previous period, indicating an increase of about 29.3%[34]. - The operating profit for the current period is CNY 586,852,374.78, up from CNY 462,867,459.03, reflecting a growth of approximately 26.8%[34]. - The basic earnings per share for the current period is CNY 0.18, compared to CNY 0.14 in the previous period, marking a 28.6% increase[36]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,327,585,381.95, an increase of 13.00% from the end of the previous year[8]. - Total assets as of September 30, 2022, were RMB 3,327,585,381.95, an increase from RMB 2,944,798,906.16 at the end of 2021[29]. - Total liabilities decreased to RMB 168,928,614.22 in Q3 2022 from RMB 288,635,135.06 in Q3 2021, indicating improved financial health[27]. - The total equity attributable to shareholders increased to RMB 3,158,656,767.73 as of September 30, 2022, from RMB 2,659,499,359.78 at the end of 2021, indicating growth in shareholder value[29]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥34,216,431.31, a decrease of 133.49% compared to the same period last year[8]. - The cash flow from operating activities for the current period is negative at CNY -34,216,431.31, a decline from CNY 102,178,130.34 in the previous period[39]. - The cash flow from investing activities shows a net inflow of CNY 429,061,638.58, compared to CNY 679,087,577.86 in the previous period, indicating a decrease of about 36.8%[39]. - The cash and cash equivalents at the end of the period amount to CNY 676,012,095.63, compared to CNY 335,200,906.36 at the end of the previous period, showing a significant increase of about 101.9%[41]. - The company's cash and cash equivalents increased to RMB 680,332,483.19 as of September 30, 2022, compared to RMB 352,996,211.31 at the end of 2021, reflecting better liquidity[20]. Cost Management - Total operating costs for the first three quarters of 2022 were RMB 447,745,546.18, down from RMB 499,050,724.03 in 2021, reflecting a cost reduction strategy[31]. - Research and development expenses decreased to RMB 9,263,286.21 in 2022 from RMB 16,864,222.85 in 2021, indicating a focus on cost management[31]. Non-Recurring Items - Non-recurring gains and losses totaled ¥112,785,927.24 for Q3 2022, primarily from the disposal of long-term equity investments[9]. - The company reported a fair value change loss of CNY -20,752,626.98 during the current period[34]. - The company recorded a tax expense of CNY 39,543,835.52 for the current period, compared to CNY 7,068,621.93 in the previous period, indicating a substantial increase in tax obligations[34]. Efficiency Metrics - The company’s accounts receivable decreased to RMB 56,298,697.14 in Q3 2022 from RMB 59,742,247.28 in Q3 2021, suggesting improved collection efficiency[20]. - The company’s inventory decreased to RMB 64,021,227.37 in Q3 2022 from RMB 80,444,934.98 in Q3 2021, indicating better inventory management[24].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 312,290,826.90, a decrease of 4.69% compared to RMB 327,661,966.34 in the same period last year[24]. - Net profit attributable to shareholders of the listed company reached RMB 397,609,700.09, an increase of 124.28% from RMB 177,282,911.90 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was RMB 88,922,688.01, down 49.94% from RMB 177,628,530.43 in the previous year[24]. - The net cash flow from operating activities was negative at RMB -14,964,185.57, a significant decline of 106.85% compared to RMB 218,529,837.64 in the same period last year[24]. - Basic earnings per share for the first half of 2022 were RMB 0.13, up 116.67% from RMB 0.06 in the same period last year[24]. - The weighted average return on net assets increased by 7.51 percentage points to 14.03% from 6.52% year-on-year[24]. - The company reported a total profit for 2022 of approximately 412.58 million, compared to 163.34 million in the previous year, indicating a significant increase[199]. - The net profit for 2022 reached approximately 376.35 million, up from 163.34 million, reflecting a growth of over 130%[199]. - Basic and diluted earnings per share for 2022 were both 0.13 yuan, compared to 0.05 yuan in the previous year, representing a 160% increase[199]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 3,340,009,894.56, reflecting a 13.42% increase from RMB 2,944,798,906.16 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company increased by 13.12% to RMB 3,008,506,774.27 from RMB 2,659,499,359.78 at the end of the previous year[24]. - Cash and cash equivalents increased by 131.73% to RMB 817,992,649.84, up from RMB 352,996,211.31, primarily due to the receipt of equity transfer payments[50]. - The company's total assets include RMB 1,430,529,930.88 in long-term equity investments, which decreased by 7.10% compared to the previous year due to disposals[50]. - The company's total liabilities include RMB 111,600,000.00 in other non-current liabilities, an increase of 80.00% due to the increase in received equity transfer payments[52]. - The company's total liabilities rose to RMB 331,437,808.97, compared to RMB 288,635,135.06, marking an increase of around 14.8%[182]. - Owner's equity increased to RMB 3,008,572,085.59 from RMB 2,656,163,771.10, showing a growth of approximately 13.3%[182]. Revenue Sources and Market Conditions - The company's main revenue sources include biopesticides, veterinary drugs, and feed additives, with a focus on environmentally friendly products[31]. - The global grain market has been volatile, impacting feed costs and the sales volume of high-end feed products[31]. - As of the end of Q2 2022, the national pig inventory was 43.057 million heads, a year-on-year decrease of 1.9%[31]. - The total industrial feed production in China from January to June 2022 was 13.653 million tons, a year-on-year decrease of 4.3%[31]. - The recent increase in pig prices is expected to play a significant role in regulating the future pig market[31]. Research and Development - The company has established partnerships with well-known universities and research institutions for new product development and process improvement[31]. - The company has established multiple laboratories equipped with advanced experimental equipment, enhancing its R&D capabilities in biological veterinary drugs and feed additives[38]. - The company is investing $30 million in research and development for new technologies aimed at improving user experience[122]. Environmental Management - The company has established an 8000T/D wastewater treatment center, ensuring compliance with environmental discharge standards[89]. - The company has implemented a comprehensive environmental emergency response plan, which was revised in August 2020 and has been approved by relevant authorities[91]. - The company’s pollution discharge indicators meet the standards set by the "Biopharmaceutical Industry Pollutant Discharge Standards" and "Coal-Fired Power Plant Air Pollutant Discharge Standards"[89]. - The company is actively pursuing green development initiatives, including the establishment of a wholly-owned subsidiary, Shanghai Hanyue Energy Technology Co., Ltd., to explore investment opportunities in the energy sector[96]. Legal and Compliance Issues - The company has taken legal action to recover accounts receivable totaling approximately 60.45 million USD from four debtors[41]. - The company has initiated legal proceedings against debtors for the recovery of 29.93 million yuan in transaction intention funds, with a repayment plan in place[70]. - The company has filed lawsuits to recover transaction intention fees totaling CNY 5,500,000.00, which remain unpaid as of the report date[132]. - The company has initiated legal proceedings against Jiangsu Jinpu Group International Trade Co., Ltd. for breaching a procurement framework agreement, seeking the return of a performance deposit of 30 million RMB and compensation for losses[144]. Strategic Initiatives - The company is focusing on integrating its chemical and thermal power supply businesses to enhance operational efficiency[31]. - The company is actively seeking investment opportunities in high-potential sectors, particularly in line with the national "14th Five-Year Plan" to explore strategic emerging industries, including renewable energy[39]. - The company plans to continue its transformation and upgrade through external investments and resource integration, although this remains subject to macroeconomic conditions and industry competition[67]. Shareholder and Governance Matters - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[6]. - The company has not made any changes to its employee stock ownership plan or other incentive measures during the reporting period[80]. - The company has committed to maintaining independence in personnel, assets, and financial operations to ensure compliance with regulatory requirements[99]. - The company has established a commitment to avoid any competitive activities that may conflict with its business interests, ensuring a focus on its core operations[109].

Financial Performance - The net profit attributable to the parent company for 2021 was ¥375,030,039.69, while the net profit for the parent company was ¥358,752,753.08[6] - The company's operating revenue for 2021 was CNY 681,244,921.86, representing a 22.60% increase compared to CNY 555,657,472.56 in 2020[24] - The net profit attributable to shareholders for 2021 was CNY 375,030,039.69, a significant recovery from a loss of CNY 942,258,861.83 in 2020[24] - The net cash flow from operating activities increased by 126.22% to CNY 105,272,394.01 in 2021, up from CNY 46,536,359.47 in 2020[24] - The basic earnings per share for 2021 was CNY 0.12, compared to a loss of CNY 0.30 per share in 2020[24] - The weighted average return on equity increased to 14.28% in 2021, up 45.28 percentage points from -31.00% in 2020[24] - The total assets decreased by 3.46% to CNY 2,944,798,906.16 at the end of 2021, down from CNY 3,050,414,098.60 at the end of 2020[24] - The net assets attributable to shareholders increased slightly by 1.04% to CNY 2,659,499,359.78 at the end of 2021[24] - Non-recurring gains and losses amounted to CNY 241,166,623.56 in 2021, significantly higher than CNY 32,851,282.26 in 2020[31] Company Strategy and Future Plans - The company plans not to distribute profits or increase capital reserves for the year 2021[6] - The company's future plans and development strategies are subject to investment risks and do not constitute substantial commitments to investors[7] - The company established a wholly-owned subsidiary, Hanye Energy, to explore investment opportunities in the new energy industry[39] - The company aims to enhance profitability and risk resistance by focusing on biotechnology and capital investment sectors, optimizing its business structure[157] - The company plans to strengthen its marketing efforts and expand its customer base to increase market share and improve profit contributions from individual clients[160] - The company will explore investment opportunities in high-potential industries, including new energy, to drive sustainable growth and maximize shareholder value[161] Risk Management and Governance - The audit report issued by Tianjian Accounting Firm (Special General Partnership) contained a qualified opinion[5] - The company has detailed potential risks in the management discussion and analysis section of the report[10] - The company has improved its internal control governance, eliminating the risk warning for its stock as of May 20, 2021[41] - The company is actively managing procurement costs by optimizing raw material inventory and production processes to mitigate risks from price fluctuations[164] - The company is focusing on R&D innovation to enhance core competitiveness amid increasing market competition in the agricultural and veterinary medicine industry[164] - The company is adjusting its product structure and improving production processes to comply with stricter environmental regulations, which may increase environmental management costs[164] Shareholder and Market Engagement - The company held five shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[167] - The company has disclosed four periodic reports and 127 temporary announcements in 2021, maintaining transparency and protecting shareholder rights[170] - The company is focused on maintaining investor relations and has utilized various communication methods to engage with stakeholders[167] - There were no rejected proposals during the recent shareholder meeting, demonstrating strong support for the company's strategic direction[175] Operational Highlights - The company repurchased a total of 86,088,593 shares, accounting for 2.75% of the total share capital, with a total payment of approximately 200 million yuan[41] - The company implemented refined management in its traditional energy sector to enhance energy efficiency and asset operation[39] - The company is currently involved in legal proceedings to recover the transaction deposit, with the case accepted by the Deqing County People's Court[95] - The company has filed for bankruptcy against the aforementioned clients in the Samoa Supreme Court, which has accepted the case[164] Industry Trends and Market Analysis - The actual sales revenue of China's gaming market in 2021 was 296.513 billion yuan, an increase of 6.4% year-on-year, with self-developed games contributing 255.819 billion yuan, up 6.51% year-on-year[48] - The mobile gaming market accounted for 76.06% of the total revenue in 2021, while client games held 19.83% and web games only 2.03%[48] - The company is the first in China to industrially produce glyphosate but faces environmental pressures and rising operational costs[110] - The pesticide industry is projected to see a decline in the number of companies from 1,705 in 2020 to below 1,600 by 2025 due to stricter environmental regulations[153] Financial Health and Investments - The company’s cash and cash equivalents increased by 363.52% to 352,996,211.31 yuan, primarily due to the recovery of receivables and dividends from associates[98] - The company’s long-term equity investments rose by 6.04% to 1,539,815,887.15 yuan, attributed to profits from associates and new external investments[98] - The company’s investment activities generated a net cash flow of ¥730,847,849.05, a 732.56% increase compared to the previous year, due to the recovery of funds and proceeds from equity disposals[91] - The company reported a total revenue of 1.2 billion RMB for the fiscal year, representing a year-over-year increase of 15%[186] Leadership and Governance Changes - The board of directors and management team have undergone changes, with several new appointments and departures, reflecting a strategic shift in leadership[179] - The independent directors received remuneration ranging from 13.85 thousand yuan to 20.00 thousand yuan, reflecting the company's governance structure[179] - The company received disciplinary actions from the Shanghai Stock Exchange for failing to disclose periodic reports and performance forecasts in a timely manner, resulting in public reprimands for multiple executives[194]

Financial Performance - The company's operating revenue for Q1 2022 was ¥158,545,781.18, representing a year-on-year increase of 2.50%[6] - The net profit attributable to shareholders of the listed company reached ¥333,681,327.24, a significant increase of 210.23% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,259,241.28, reflecting a decrease of 75.98% year-on-year[6] - Basic and diluted earnings per share were both ¥0.11, an increase of 266.67% year-on-year[6] - The weighted average return on equity was 11.80%, an increase of 6.83 percentage points compared to the previous year[6] - Total operating revenue for Q1 2022 was RMB 158,545,781.18, an increase of 2.8% compared to RMB 154,686,061.60 in Q1 2021[29] - Net profit for Q1 2022 reached RMB 333,682,227.24, compared to RMB 107,540,372.20 in Q1 2021, representing a significant increase of 210.5%[33] - Total comprehensive income for the period was CNY 334,709,783.46, compared to CNY 106,942,796.92 in the previous year, representing a significant increase[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,264,814,479.80, up 10.87% from the end of the previous year[9] - The equity attributable to shareholders of the listed company increased to ¥2,944,202,828.81, a rise of 10.71% year-on-year[9] - As of March 31, 2022, the company's total assets amounted to RMB 3,264,814,479.80, an increase from RMB 2,944,798,906.16 as of December 31, 2021[21] - Total liabilities as of the reporting date were RMB 324,995,013.49, compared to RMB 288,635,135.06 in the previous year, indicating a year-over-year increase of 12.6%[29] - Total equity attributable to shareholders was RMB 2,944,202,828.81, up from RMB 2,659,499,359.78 in the previous year, reflecting an increase of 10.7%[29] Cash Flow - The net cash flow from operating activities was negative at -¥2,931,825.92, a decline of 102.74% compared to the previous year[6] - Cash inflows from operating activities totaled CNY 98,947,045.82, a decrease of 51.49% from CNY 204,033,090.47 in the previous year[38] - The net cash flow from operating activities was negative at CNY -2,931,825.92, contrasting sharply with CNY 106,999,854.69 in the prior year[38] - Cash inflows from investment activities amounted to CNY 454,260,536.23, down from CNY 523,400,092.23, reflecting a decline of 13.23%[38] - The net cash flow from investment activities was CNY 349,202,721.31, an increase of 77.06% compared to CNY 197,285,609.50 in the previous year[38] - The net cash flow from financing activities was CNY -68,773,144.43, an improvement from CNY -125,920,222.43 in the same period last year[40] - The total cash and cash equivalents at the end of the period were CNY 628,794,853.07, compared to CNY 254,598,312.08 at the end of the previous year, showing an increase of 146.67%[40] Operational Metrics - The company reported a significant decline in the performance of its amino acid products due to market conditions, impacting the net profit attributable to shareholders after deducting non-recurring gains and losses[10] - The company's cash and cash equivalents reached RMB 648,939,722.12, up from RMB 352,996,211.31 year-over-year[21] - Total current assets increased to RMB 1,152,596,303.84 from RMB 729,712,183.70, reflecting a growth of approximately 57.8%[24] - The company's accounts receivable rose to RMB 61,617,922.03, compared to RMB 59,742,247.28 in the previous year[21] - The company's inventory decreased to RMB 57,234,720.01 from RMB 80,444,934.98, indicating a reduction of approximately 29%[21] - The company reported a significant increase in other receivables, which rose to RMB 263,566,315.83 from RMB 92,025,970.10[21] Shareholder Information - The total number of shares held by major shareholders indicates a potential change in control, with the largest shareholder holding 22.22% of shares[20] - The company has a share repurchase account holding 170,768,742 shares, representing 5.48% of the total share capital[20] - The company anticipates a change in its controlling shareholder due to the judicial disposal of shares held by a major shareholder[20] Expenses - Total operating costs for Q1 2022 were RMB 172,673,930.63, up from RMB 155,280,385.33 in Q1 2021, reflecting a year-over-year increase of 11.2%[29] - Research and development expenses for Q1 2022 were RMB 4,178,493.77, down 32.5% from RMB 6,207,303.29 in Q1 2021[29] - The company reported a decrease in tax expenses to RMB 1,388,624.66 in Q1 2022 from RMB 1,982,092.88 in Q1 2021, a reduction of 30%[29] - The company reported a decrease in cash outflows for employee payments to CNY 23,385,055.43 from CNY 28,177,323.59, a reduction of 17.73%[38] - The company experienced a decrease in cash outflows related to taxes paid, which totaled CNY 2,906,127.70, down from CNY 4,164,436.04, a decline of 30.19%[38]

Financial Performance - The company's operating revenue for Q3 2021 was ¥160,850,706.45, representing a year-on-year increase of 14.73%[7] - The net profit attributable to shareholders for Q3 2021 was ¥268,920,294.08, a significant increase of 565.99% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥44,257,377.34, up by 6.17% year-on-year[7] - The basic earnings per share for Q3 2021 was ¥0.09, reflecting an increase of 800% compared to the same period last year[10] - The diluted earnings per share for Q3 2021 was also ¥0.09, with a similar increase of 800% year-on-year[10] - Operating profit for the third quarter of 2021 was ¥462,867,459.03, significantly up from ¥200,018,846.10 in the previous year, indicating an increase of approximately 131.3%[34] - Net profit for the third quarter of 2021 was ¥446,202,294.92, compared to ¥191,366,448.04 in the same quarter of 2020, reflecting a growth of around 133.3%[34] - Earnings per share for the third quarter of 2021 were ¥0.14, up from ¥0.06 in the same quarter of 2020, marking a 133.3% increase[36] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥3,070,318,581.84, a slight increase of 0.65% from the end of the previous year[10] - The equity attributable to shareholders at the end of Q3 2021 was ¥2,757,068,261.03, up by 4.75% compared to the end of the previous year[10] - The total assets of the company reached ¥3,070,318,581.84, compared to ¥3,050,414,098.60 in the previous year, reflecting a growth of about 0.65%[26] - The total liabilities decreased to ¥316,567,884.64 from ¥421,832,456.44, showing a reduction of approximately 25%[29] - The total equity attributable to shareholders of the parent company increased to ¥2,757,068,261.03 from ¥2,632,006,532.97, representing a growth of approximately 4.8%[34] - Total liabilities amounted to 421,832,456.44, with current liabilities at 390,721,819.34[47] - The total current liabilities represent a significant portion of the overall liabilities, indicating liquidity management[47] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥102,178,130.34, reflecting a significant increase of 199.29%[10] - Cash flow from operating activities increased to ¥102,178,130.34, up from ¥34,139,717.82 year-over-year, representing a significant growth[40] - The company’s cash inflow from operating activities totaled ¥664,077,872.58, compared to ¥364,995,641.65 previously, indicating improved operational efficiency[40] - The company reported a total cash and cash equivalents balance of ¥335,200,906.36 at the end of the period, compared to ¥46,770,518.15 in the previous year[42] - Total cash inflow from investment activities reached ¥921,279,578.51, compared to ¥82,253,290.87 in the previous period, indicating a substantial increase[42] - Net cash flow from financing activities was negative at -¥505,191,366.29, worsening from -¥126,252,767.20 year-over-year, reflecting higher outflows[42] Investments and Expenses - The company completed the sale of part of its equity in an associate, which contributed to the significant increase in net profit for the period[12] - The company reported a decrease in research and development expenses to ¥16,864,222.85 from ¥30,803,914.40 year-over-year, a reduction of about 45.1%[34] - Financial expenses significantly decreased to ¥845,421.30 from ¥17,958,312.81, indicating a reduction of approximately 95.3%[34] - The company’s investment income received cash was ¥159,526,135.81, showing a strong performance in investment returns[40] - Cash outflow for investment activities was ¥242,192,000.65, significantly higher than ¥13,447,342.06 in the previous period[42] Receivables and Provisions - The accounts receivable increased to ¥55,365,590.05 from ¥27,194,851.04 year-over-year, indicating a growth of approximately 103.5%[26] - The company has filed for bankruptcy against four clients with a total accounts receivable of ¥342,431,800, which has been fully provisioned for bad debts[22] - The company's other receivables decreased significantly from ¥601,368,389.86 to ¥193,411,221.60, indicating a reduction of approximately 67.9%[26] - The company reported a total of ¥15,238,392.93 in contract liabilities, down from ¥23,162,373.14, reflecting a decrease of about 34.5%[29]